Insuline Medical Stock Fundamentals
| INSL Stock | ILS 196.00 20.90 9.64% |
Insuline Medical fundamentals help investors to digest information that contributes to Insuline Medical's financial success or failures. It also enables traders to predict the movement of Insuline Stock. The fundamental analysis module provides a way to measure Insuline Medical's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Insuline Medical stock.
Insuline |
Insuline Medical Company EBITDA Analysis
Insuline Medical's EBITDA stands for earnings before interest, taxes, depreciation, and amortization. It is a measure of a company operating cash flow based on data from the company income statement and is a very good way to compare companies within industries or across different sectors. However, unlike Operating Cash Flow, EBITDA does not include the effects of changes in working capital.
Current Insuline Medical EBITDA | (6.82 M) |
Most of Insuline Medical's fundamental indicators, such as EBITDA, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Insuline Medical is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
In a nutshell, EBITDA is calculated by adding back each of the excluded items to the post-tax profit, and can be used to compare companies with very different capital structures.
| Competition |
According to the company disclosure, Insuline Medical reported earnings before interest,tax, depreciation and amortization of (6.82 Million). This is 100.78% lower than that of the Healthcare sector and 101.06% lower than that of the Medical Devices industry. The ebitda for all Israel stocks is 100.17% higher than that of the company.
Insuline Medical Fundamental Drivers Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Insuline Medical's current stock value. Our valuation model uses many indicators to compare Insuline Medical value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Insuline Medical competition to find correlations between indicators driving Insuline Medical's intrinsic value. More Info.Insuline Medical is rated third overall in price to earning category among its peers. It is rated fourth overall in revenue category among its peers . Comparative valuation analysis is a catch-all model that can be used if you cannot value Insuline Medical by discounting back its dividends or cash flows. This model doesn't attempt to find an intrinsic value for Insuline Medical's Stock. Still, instead, it compares the stock's price multiples to a benchmark or nearest competition to determine if the stock is relatively undervalued or overvalued.Insuline EBITDA Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Insuline Medical's direct or indirect competition against its EBITDA to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Insuline Medical could also be used in its relative valuation, which is a method of valuing Insuline Medical by comparing valuation metrics of similar companies.Insuline Medical is rated third overall in ebitda category among its peers.
Insuline Fundamentals
| Price To Earning | (40.77) X | |||
| Revenue | 40 K | |||
| EBITDA | (6.82 M) | |||
| Net Income | (7.01 M) | |||
| Cash And Equivalents | 1.15 M | |||
| Cash Per Share | 2.86 X | |||
| Current Ratio | 0.98 X | |||
| Book Value Per Share | (0.16) X | |||
| Cash Flow From Operations | (7.68 M) | |||
| Earnings Per Share | (30.78) X | |||
| Number Of Employees | 26 | |||
| Beta | 1.79 | |||
| Market Capitalization | 36.33 M | |||
| Total Asset | 1.58 M | |||
| Retained Earnings | (158 M) | |||
| Working Capital | (1000 K) | |||
| Current Asset | 8 M | |||
| Current Liabilities | 9 M | |||
| Net Asset | 1.58 M |
About Insuline Medical Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Insuline Medical's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Insuline Medical using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Insuline Medical based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.Yaad Sihan Projects Management and Entrepreneurship Ltd. is headquartered in Jerusalem, Israel. Insuline Medical is traded on Tel Aviv Stock Exchange in Israel.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Other Information on Investing in Insuline Stock
Insuline Medical financial ratios help investors to determine whether Insuline Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Insuline with respect to the benefits of owning Insuline Medical security.